Abstract
Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Medicinal Chemistry
Title:3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Volume: 9 Issue: 5
Author(s): Oleg V. Ardashov, Alla V. Pavlova, Dina V. Korchagina, Konstantin P. Volcho, Tat’ yana G. Tolstikova and Nariman F. Salakhutdinov
Affiliation:
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Abstract: Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Export Options
About this article
Cite this article as:
Ardashov V. Oleg, Pavlova V. Alla, Korchagina V. Dina, Volcho P. Konstantin, Tolstikova G. Tat’ yana and Salakhutdinov F. Nariman, 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050013
DOI https://dx.doi.org/10.2174/1573406411309050013 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Analysis of Flavin-Containing Monooxygenase 3 Genotype Data in Populations Administered the Anti-Schizophrenia Agent Olanzapine
Drug Metabolism Letters Novel Directions in Antipsychotic Target Identification using Gene Arrays
Current Drug Targets - CNS & Neurological Disorders Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Selective Targeting of Muscarinic Receptors: Novel Therapeutic Approaches for Psychotic Disorders
Current Neuropharmacology Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Neural Stem Cells: From Neurobiology to Clinical Applications
Current Pharmaceutical Biotechnology Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research